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The average life-span of the population of industrialized countries has improved enormously over the last decades.
Despite evidence pointing to the role of food intake in modulating life-span, exceptional longevity is still considered
primarily an inheritable trait, as pointed out by the description of families with centenarian clusters and by the
elevated relative probability of siblings of centenarians to become centenarians themselves. However, rather than
being two separate concepts, the genetic origin of exceptional longevity and the more recently observed
environment-driven increase in the average age of the population could possibly be explained by the same genetic
variants and environmentally modulated mechanisms (caloric restriction, specific nutrients). In support of this
hypothesis, polymorphisms selected for in the centenarian population as a consequence of demographic pressure
have been found to modulate cellular signals controlled also by caloric restriction. Here, we give an overview of the
recent findings in the field of the genetics of human exceptional longevity, of how some of the identified
polymorphisms modulate signals also influenced by food intake and caloric restriction, of what in our view have
been the limitations of the approaches used over the past years to study genetics (sib-pair-, candidate gene
association-, and genome-wide association-studies), and briefly of the limitations and the potential of the new,
high-throughput, next-generation sequencing techniques applied to exceptional longevity.
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Life expectancy in the US 1900 Birth Cohort Study was
found to be 51.5 years for males and 58.3 years for
females, and currently 1/10,000 individuals reach
100 years of age: this prevalence is quickly changing and
will probably soon approach 1/5,000 [1]. The increased
ability to reach 100 years old in industrialized countries
over the last 160 years most likely reflects a rise in life
expectancy — quantified as 3 months/year for females —
as a consequence of improvements in diet and a reduced
exposure to infection and inflammation [2]. In favour of
diet as a modulator of longevity, the Elderly Prospective
Cohort Study (EPIC) identified a reduced overall mortality
among the elderly consuming a modified Mediterranean* Correspondence: puca@longevita.org
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reproduction in any medium, provided the ordiet in which saturated fatty acids were substituted for
monounsaturated ones [3].
Centenarians, despite being exposed to the same environ-
mental conditions as members of the average population,
manage to live much longer; moreover, as a consequence
of demographic selection, centenarians have a compres-
sion of morbidity and mortality towards the end of their
life-span [4]. Genetically, this compression in morbidity
and mortality is correlated with the enrichment of pro-
tective alleles and the depletion of detrimental ones.
These alleles run in families, as shown by the familiar
clustering of exceptional longevity. It has been estimated
that genetic variants account for at least 25% of human
life-span, and for even a larger proportion in individuals
living to extreme age [5,6].
The potential overlap of hits for environmentally and
genetically mediated predisposition for extreme longevity
in centenarians is highlighted by the association of
genetic variants of genes that regulate, or that areLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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tein E (APOE) and Forkhead box O3A (FOXO3A) [7].
Inheritance of the longevity phenotype is underlined by
the low all-cause and cardiovascular-disease mortality
rates observed in offspring of centenarians when com-
pared with an age-matched population [8]. The study of
centenarian offspring has revealed biomarkers of longev-
ity, like low serum levels of heat shock proteins (HSP),
large lipid particle sizes, and high membrane palmitoleic
acid paired with a low peroxidation index [9-11]. In
addition, centenarians have high glucose tolerance and
insulin action, and low heart-rate variability (HRV),
which contrasts with the decline observed in control
populations [12,13].
Genetic variants that modulate human longevity
should also modulate cellular pathways that control key
aspects of the aging process, such as oxidative stress-
induced apoptosis (RAS/ERK pathway), DNA repair
(NF-KB1 and hTERT), senescence (p53), mitochondrial
biogenesis (AMPK) and cell survival (PI3K/AKT path-
way). Many of these pathways cross-talk with each other
and are finely regulated in order to obtain the best trade-
off between advantages and disadvantages of inducing
either cell survival or apoptosis/senescence. The best
trade-off is mostly tissue specific and can change with
the degree of the tissue’s differentiation (stem versus dif-
ferentiated cells) and health status (healthy, proliferative,
degenerative or ischemic). It is plausible that genetic
variants that impact on human longevity affect genes
that are expressed selectively in some tissues and/or in
specific stages of differentiation. Although aging has been
considered an evolutionary adaptation for fighting cancer
through the activation of processes like senescence, there
are signals that are able to activate cell-specific responses,
e.g. induction of apoptosis by adenosine monophosphate-
activated protein kinase (AMPK) in cancer cells, while
inducing survival in healthy cells. AMPK recognizes high
levels of AMP, and is activated by caloric restriction,
physical exercise, metformin, essential amino acids and
alpha-lipoic acid [14]. Furthermore, AMPK induces
mitochondrial biogenesis, autophagy and beta-oxidation
of free fatty acids [15-17]. Reduction of fatty acid beta-
oxidation promotes diabetes, obesity and, ultimately,
aging.
How can these cellular signals be altered without pro-
ducing side effects? The answer could be found in the
centenarian genome through the identification of genetic
variants that have been selected or dropped for their role
in human health. AMPK signalling is an example of how
variation in the quality and the amount of food could
impact on longevity by modulating signals that are influ-
enced by genetic variants selected in centenarians. To be
noted, Sirtuin 1 (SIRT1), despite its role in many cellular
processes, induces survival and is not affected bypolymorphisms that associate with exceptional longevity
in humans, perhaps on account of its critical role in
tumours as well [18].The candidate gene approach and associations
with longevity
To date, only a few genetic variants have been consist-
ently found associated with exceptional longevity in
humans (Table 1). The most convincing result discovered
to date by a candidate gene approach is the reduction of
the APOE 4 allele in centenarians as a result of its cor-
relation with cardiovascular disease and Alzheimer’s
disease [7]. APOE knockout mice develop atherosclerosis,
so genes that modulate vascular integrity are potential
candidates that may be identified in genetic association
studies of exceptional longevity [19].
The FOXO3A rs2802292 allele is another variant
found associated with exceptional longevity across popu-
lations [20,22-24]. Nevertheless, this polymorphism has
no apparent impact on the functions of FOXO3A and it
is not in LD with functional variants. However, FOXO3A
is part of a pathway associated with longevity: IGF1/
PI3K/PDK1/AKT/FOXO. Animal studies from worms to
mice have shown that genetic modifications are able to
postpone aging by modulating the IGF1/PI3K/PDK1/
AKT/FOXO pathway [25]. This pathway regulates many
aspects of cell homeostasis, from cell survival and prolifera-
tion to oxidative stress response, depending on concomi-
tant stimuli [26,27]. Interestingly, individuals with short
stature due to a lack of growth hormone, which is up-
stream of the IGF1/PI3K/PDK1/AKT/FOXO pathway,
have a reduced incidence of tumours and diabetes [28].
The IGF1/PI3K/PDK1/AKT/FOXO pathway is strongly
modulated by caloric restriction, as are the levels of AMPK
and SIRT1. Glucose and insulin resistance also modulates
this pathway, which associates with inefficient uptake of
glucose, inducing its overstimulation and aging. To some
extent, genetic alterations of the insulin-like growth factor
1 (IGF1) receptor that alter the IGF signalling pathway
confer an increase in propensity for longevity [29].
Adenosine deaminase, RNA-specific (ADAR) and
telomerase gene variants have also been associated with
human longevity [30,31]. However, with the exception of
APOE and FOXO3A variants, none of the many candidate
genetic variants tested to date have been consistently repli-
cated across populations. This is possibly on account of
differing environmental stimuli generating inconsistent
demographic pressures, making results, as a consequence,
irreproducible [32].
Other potential problems that generate false positive
and false negative results include the low power of stud-
ies using small sample sizes, and a lack of a suitable
control for the genetic admixture. On the first point, an
Table 1 Genes and variants found correlated with longevity in humans
Gene Variant Occurrence in centenarians Previous disease correlations Potential role in longevity Ref.
APOE ε4* reduced Alzheimer’s and cardiovascular diseases Maintenance of vascular integrity [7]
FOXO3A rs2802292* more present none Control of cell homeostasis [20]
CAMK4 rs10491334† more present hypertension Modulation of CREB, SIRT and FOXO3A [21]
ATXN1 rs697739 more present amyotrophic lateral sclerosis (age of onset) Modulation of CREB [21]
DCAMKL1 rs9315385 more present heart rate variability Modulation of CREB [21]
*, result obtained by a candidate gene approach and replicated in other studies; †, result obtained from a GWAS and confirmed in a replication cohort.
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Altshuler, Daly and Lender, who calculate the power of
a study based on the number of individuals genotyped,
the number of tested hypotheses, and the frequency of
the allele tested for a specific OR [33]. From the graph
given in their review (Figure 1), it is clear that for the
OR expected in human exceptional longevity (between
1.2 and 2), the power of a study is highly dependent
upon the number of hypotheses tested. If we consider
that many laboratories test their genetic variants and
publish only the positive results they find, the few hun-
dred individuals typically used in a candidate gene
approach on exceptional longevity are not sufficient to
minimize false-positive findings.
With regard to the appropriate control for a given genetic
admixture, it is possible to correct for systematic ancestry
differences between cases and controls — an effect that can
cause false associations — by the application of principalFigure 1 Sample sizes required for genetic association studies. The gr
N/2 controls) required to map a genetic variant as a function of the increas
the disease-causing allele (various curves). The required sample size is show
studies [33]. Reproduced with permission from The American Association focomponents analysis to the genotyping of thousands of
SNPs with chips [34].
Finally, because the candidate gene approach is hy-
pothesis driven, the functional validation of the coded
protein in signals important for aging and longevity do
not add strength to the finding, while as we will see, this
is an opportunity for hypothesis-free approaches, such as
the genome-wide association study (GWAS) and sib-pair
analysis.
Genome-wide association studies and exceptional
longevity
GWASs are hypothesis-free efforts that generate findings
that need to be replicated in independent populations. In
the case of exceptional longevity, success in replicating
initial findings is negatively influenced by the differences
in participant ages, gender and disease status distribution
across the analysed populations. Furthermore, theaph shows the total number N of samples (consisting of N/2 cases and
ed risk due to the disease-causing allele (x axis) and the frequency of
n in the table on the right for various different kinds of association
r the Advancement of Science.
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tical penalty that forces the adoption of very low p values
of significance, hence favouring the phenomenon of the
winning course, i.e. the enrichment of false-positive asso-
ciations among the dozens of top findings [35]. For these
reasons, recent GWASs have failed to find variants that
cross-validate across populations — with the exception
of the known APOE locus — pointing to the need of
much larger studies or alternative study designs in order
to discover common polymorphisms with smaller genetic
effects and rare variants with high penetrance that
influence exceptional longevity [36,37].
Regarding the power of capturing true associations in
GWAS efforts, the Altshuler, Lander and Daly review
calculation clearly shows that a sample size comprising
thousands of individuals is needed to identify the
expected OR in a GWAS on exceptional longevity [33].
Thus, a GWAS on exceptional longevity can be considered
only a hypothesis-generating effort to be used in conjunc-
tion with other studies.
For the above reasons, in our recently published
GWAS on individuals enrolled in the Southern Italian
Centenarian Study (SICS), we not only attempted to pro-
gressively reduce the number of tested hypotheses, but
also considering the redundancy (non-independence) of
the many SNPs represented on the Illumina 317 k bead-
chip employed, we decided to use a 300 k SNP screening
of the SICS individuals as a hypothesis-generating set,
adopting a Genomic Control (GC)-corrected p-value
< 1e-4 threshold (which is a less stringent threshold than
p< 5x10-2/317000 = 1.5x10-7) for the replication, evalu-
ating allelic, genotypic, dominant and recessive genetic
association models [21].
Initial screening of SICS individuals identified CAMK4
rs10491334, a variant that had been already established
among the top 5 SNPs in the Framingham Heart Study
on diastolic high blood pressure [38]. The fact that
CAMK4 rs10491334 associates also with hypertension is
reassuring in that hypertension and longevity are regu-
lated by common pathways. In fact, mice with genetic
ablation of the angiotensin II type1 receptor — the key
regulator of blood pressure — had increased expression
of the longevity gene Sirt3 and improved survival [39].
Interestingly, rs10491334 correlated with CAMK4 protein
expression, and functional studies revealed the ability of
CAMK4 protein to modulate SIRT1 and FOXO3A.
The ataxin-1 (ATXN1) rs697739 allele was another vari-
ant found among the top findings of our GWAS on SICS
individuals. This polymorphism had been previously asso-
ciated with the age of onset of sporadic amyotrophic lateral
sclerosis, a disease of unknown cause characterized by
slowly progressive degeneration of motor neurons and that
usually occurs in patients aged 40–60 years [40]. ATXN1 is
the gene responsible for spinocerebellar ataxia type 1 andantagonizes the neuronal survival function of myocyte
enhancer factor-2 (MEF2) [41].
MEF2 transcription repression by cabin1-HDAC4 is
removed by CAMKIV activation, and this suggests that
MEF2 is a common downstream target of CAMKIV and
ATXN1 [42,43].
In addition to CAMKIV rs10491334 and ATXN1
rs697739, the rs9315385 allele of doublecortin and
Ca2+/calmodulin-dependent kinase-like-1 (DCAMKL1)
was a third top finding of our study. DCAMKL1 has
structural similarity with CAMKIV, but despite this,
it represses CAMKIV-induced activation of cAMP
response element-binding (CREB) protein via phos-
phorylation of transducer of regulated CREB activity
2 (TORC2) at Ser171 [44]. DCAMKL1 rs9315385 was
previously associated with total power of HRV [45].
A reduced HRV is a marker of autonomic dysfunction and
is associated with an increased risk of cardiovascular mor-
bidity and mortality [46]. HRV-parasympathetic function
decreases up to the eighth decade of life, followed by an
increase to higher levels — similar to those found in a
younger population — in nonagenarians and centenarians
[13]. Similarly to CAMKIV, DCAMKL1 and ATXN1 are
expressed mainly in brain. These data support the import-
ance of the CAMKIV/CREB pathway in regulating the
aging process.
A brief mention needs to be made here on the cutting-
edge, genetic signature paper by Sebastiani et al. that
very elegantly proved that a complex analysis on 281
SNPs allowed to define clusters of individuals that aged
differently based on their genetic signature [47].
Linkage analysis and exome sequencing
Sib-pair analysis has been for a while the only tool avail-
able for the identification of chromosomal regions that
potentially harbour genetic variants influencing the
phenotype of interest. The approach can identify excess
allele sharing, and was initially performed with microsa-
tellites. It consists in the identical-by-descendant analysis
of very informative markers that reconstruct the haplo-
type of parents and how they co-segregate in their off-
spring. We performed such an analysis on a unique
collection of sib-pairs and their families, collected by the
New England Centenarian Study (NECS), and identified
a significant peak on 4q25 [48]. Follow-up analysis failed
to identify genetic variants that could explain the initial
linkage finding. Rare mutations that segregate in centen-
arian siblings are eventually captured by sibling-pair ana-
lysis, but this cannot be the case for genetic association
studies that loose power as the allele frequency of the
tested polymorphisms drops. Furthermore, it is possible
that linkage efforts identify chromosomal regions where
more causative genetic variants reside, and thus the sum
of their effects determines the linkage result, whereas
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lysis involves one common polymorphism at a time or,
eventually, haplotypes. Attempts to replicate the initial
linkage did not succeed, except for an initial replication
effort that successfully replicated the linkage at D4S1564
[49,50]. A negative replication effort can be due to an
initial false-positive finding or to the diversity of the
populations used for the replication effort, in terms of
genetic background, the environment applying the
demographic pressure, the ages of the participants, the
number of families and the genetic markers adopted.
Recently, Kunkel’s laboratory published a well-performed
re-analysis of a part of the sib-pairs used in the initial
study, plus new sib-pairs recruited by Elixir Pharmaceu-
ticals [51]. To be noted, some of the largest and more
impressive families — those that were genotyped upfront
and that showed immediately a significant linkage on
4q25 in the original study — were either not analysed or
done so only in part by this second effort. The new ana-
lysis adopted a high-density marker panel of SNPs to
genotype the patients, allowing a better coverage of the
genome. They did not replicate the chromosome 4q25
finding, except when the same stringent criteria were
adopted to select a sub-set of centenarian families. Inter-
estingly, a new peak on chromosome 3p24-22 reached
significant threshold, and a second peak was highly
suggestive of linkage at 9q31-34. This latter peak
appeared also in the previous analysis with microsatel-
lites, even if less robustly. The attempt to identify the
genetic variant/variants responsible for the 4q25 peak
pointed to the initial encouraging genetic variant in the
promoter of the microsomal triglyceride transfer protein
(MTP) gene [52]. Unfortunately, the finding was not
replicated by an independent effort and by our analysis
that included more controls [32,53].
It is plausible that different approaches are needed to
follow up genetic linkage findings, to point to the identifi-
cation of rare variants that co-segregate in families. To this
end, exome sequencing data, intersected with linkage data,
could give rise to interesting results.
To be noted, the 4q25 locus harbours elongation of
very long chain fatty acids protein 6 (ELOVL6), the elon-
gase that transforms C16:0 into C18:0 and C16:1 into
C18:1. Polymorphisms in this gene have been associated
with insulin sensitivity; a mouse deficient for this gene
carried high doses of C16:1 (palmitoleic acid) and did
not acquire insulin resistance after a high-fat diet
[54,55]. C16:1 has been identified as an adipose tissue-
derived lipid hormone that strongly stimulates muscle
insulin action and suppresses hepatosteatosis [56]. Gen-
etically modified, long-living worms have an incredible
correlation between their increase in life-span and their
palmitoleic acids levels [57]. This is stunning if we con-
sider the increased level of palmitoleic acid that weobserved in centenarians’ offspring and that the gene of
the major modifier of palmitoleic acid levels (i.e.
ELOVL6) is located in the 4q25 longevity locus [11,48].
The re-sequencing in centenarians of this gene could
bring to the identification of rare variants able to
influence its activity.
Thus, the old approach of linkage analysis when com-
bined with the new technologies of high massive re-
sequencing could produce novel and interpretable
results. Re-sequencing alone, because of the enormous
amount of information generated, would force the appli-
cation of a huge statistical correction for the multiple
testing, which would cause the loss of most, if not all,
the potential findings, as happens with GWAS.
Furthermore, multivariate models, based on machine-
learning algorithms (i.e. Bayesian networks [58], classifi-
cation and regression trees — CART [59] — and support
vector machines — SVM [60]), are able to overcome the
limitations of the usual “one-SNP-at-the-time” testing
strategies usually employed for identifying causative var-
iants. In particular, these kinds of approaches allow for a
more in-depth comprehension of the molecular mechan-
isms underlying multifactorial traits, such as longevity,
which result from the interaction of genetic variants
(SNPs, mutations) and environmental and clinical deter-
minants (e.g. diet, stress, comorbidities). In this context,
bioinformatics plays a key role, allowing genetic informa-
tion to be managed at a genome-wide level and to be
integrated with the clinical information available.Concluding remarks
Despite the enormous progress achieved by DNA-
investigating technologies, such as SNP arrays and
exome capturing/re-sequencing, the current know-
ledge on how genetic variants influence exceptional
longevity in humans is still based on the old candi-
date gene approaches. The adoption of innovative
study designs combined with novel genetic platforms
and innovative statistical methods hopefully will bring
to the identification of new intervention points at
which to modulate aging and the diseases of aging.Abbreviations
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